Frequently Asked Questions
Have questions about our platform or your account? We’ve provided answers to the most commonly asked clinical questions about BrainCheck here. Patients and caregivers, please visit our patient site.
Questions About Our Platform
The BrainCheck platform is a comprehensive set of cognitive health assessments, screeners and digital biomarkers designed for everyday clinical use, allowing providers and caregivers to assess and address cognitive concerns earlier and more effectively than ever before.
BrainCheck is designed to be used by reimbursing clinicians and value-based care providers. This includes primary care physicians (primary care, neurologists, geriatricians, psychiatrists), doctoral-level clinical psychologists, clinical nurse specialists, nurse practitioners and more. BrainCheck assessments can be administered by physician assistances, med-techs, and other clinical staff.
BrainCheck is a diagnostic aide, not a stand-alone diagnostic. BrainCheck gives providers and patients a snapshot of how patients’ brains are working in several different cognitive domains.
Questions About Your Account
Questions About Our Cognitive Assessments
Clinical rationales for ordering cognitive assessments include (but are not limited to) to address subjective complaints by a patient or family member, to aid in confirming or establishing a diagnosis, and to track progression or improvement of diagnosed cognitive impairment. For accurate results, we recommend that the test should not be ordered for anyone younger than ten.
BrainCheck’s assessments are randomized each time a test is taken. No person will ever take the exact same test twice. This means that BrainCheck tests cannot be memorized or practiced. Should a score fall outside of normal range, the result of that particular assessment is flagged, allowing providers and to identify potential problems.
All of the information BrainCheck collects is encrypted and stored on secure, HIPAA-compliant servers. Because we are dedicated to improving our understanding of cognitive impairment and the brain, we use the wealth of information in our database to discover new correlations. Privacy is the most important thing to us, so the data we use in our analytics is always anonymous and never tied to patient names.
The AMA’s proposals met a shared goal with CMS, putting patients over paperwork and improving
November is National Alzheimer’s Awareness Month. The general public’s perception of the disease is that